Rubius Therapeutics

OverviewSuggest Edit

Rubius Therapeutics is developing Red-Cell Therapeutics™ (RCTs™) as a new class of medicines to address a wide array of indications, with leading applications in cancer, rare and autoimmune disease, as well as additional potential in hemophilia, infectious and metabolic diseases.

TypePublic
Founded2013
HQCambridge, MA, US
Websiterubiustx.com

Latest Updates

Employees (est.) (Apr 2019)174(+23%)
Job Openings30
Share Price (Jul 2021)$21.5(-5%)
Cybersecurity ratingAMore

Key People/Management at Rubius Therapeutics

Pablo J. Cagnoni

Pablo J. Cagnoni

Chief Executive Officer, Director
Christina Coughlin

Christina Coughlin

Chief Medical Officer
Andrew Oh

Andrew Oh

Chief Financial Officer
Kris Elverum

Kris Elverum

Senior Vice President, Business Development and Strategy
Spencer Fisk

Spencer Fisk

Senior Vice President & Chief Technical Operations Officer
Bryan Gillis

Bryan Gillis

Vice President, Manufacturing
Show more

Rubius Therapeutics Office Locations

Rubius Therapeutics has offices in Cambridge and Smithfield
Cambridge, MA, US (HQ)
399 Binney St #300
Smithfield, RI, US
100 Technology Way
Show all (2)

Rubius Therapeutics Financials and Metrics

Rubius Therapeutics Revenue

USD

Net income (Q1, 2021)

(42.3m)

EBIT (Q1, 2021)

(40.9m)

Market capitalization (30-Jul-2021)

1.9b

Closing stock price (30-Jul-2021)

21.5

Cash (31-Mar-2021)

288.1m

EV

1.7b
Rubius Therapeutics's current market capitalization is $1.9 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

General and administrative expense

2.4m22.0m39.9m57.2m50.3m

R&D expense

8.4m21.2m51.8m112.4m116.1m

Operating expense total

10.9m43.3m91.7m169.6m166.4m

EBIT

(10.9m)(43.3m)(91.7m)(169.6m)(166.4m)
Quarterly
USDQ1, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

General and administrative expense

1.1m5.8m16.3m13.2m13.5m13.8m15.0m12.7m11.6m13.2m

R&D expense

3.7m9.7m12.0m14.4m20.9m27.5m33.5m36.2m26.1m27.7m

Operating expense total

4.8m15.4m28.2m27.6m34.4m41.3m48.5m48.9m37.7m40.9m

EBIT

(4.8m)(15.4m)(28.2m)(27.6m)(34.4m)(41.3m)(48.5m)(48.8m)(37.7m)(40.9m)
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

6.8m104.3m307.1m91.9m91.2m

Prepaid Expenses

53.0k700.0k

Current Assets

6.9m105.0m414.4m289.3m181.5m

PP&E

868.0k2.4m62.8m56.9m54.0m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

136.5m116.9m354.8m192.5m141.1m109.6m144.5m129.2m288.1m

Prepaid Expenses

838.0k

Current Assets

193.6m182.8m412.5m385.8m366.6m329.8m245.9m244.1m336.3m

PP&E

14.3m21.1m39.2m24.6m41.9m52.5m56.4m55.6m53.3m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(11.0m)(43.8m)(89.2m)(163.5m)(167.7m)

Depreciation and Amortization

118.0k447.0k1.3m3.0m5.7m

Accounts Payable

589.0k1.1m4.9m(1.0m)(1.4m)

Cash From Operating Activities

(9.5m)(21.9m)(58.3m)(110.4m)(127.6m)
Quarterly
USDQ1, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(4.9m)(15.3m)(44.4m)(62.0m)(32.6m)(72.0m)(119.0m)(42.3m)

Depreciation and Amortization

48.0k227.0k502.0k879.0k661.0k1.4m2.3m1.8m3.6m1.5m

Accounts Payable

937.0k452.0k3.0m2.4m(966.0k)(4.7m)3.2m905.0k3.1m(757.0k)

Cash From Operating Activities

(3.1m)(10.9m)(20.8m)(38.6m)(22.9m)(52.7m)(81.5m)(40.0m)(68.6m)(38.7m)
USDFY, 2016

Debt/Equity

6.3 x

Debt/Assets

1.5 x

Financial Leverage

4.1 x
Show all financial metrics

Rubius Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Rubius Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Rubius Therapeutics Online and Social Media Presence

Embed Graph

Rubius Therapeutics News and Updates

Rubius Therapeutics Appoints Dannielle Appelhans as Chief Operating Officer

CAMBRIDGE Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer an…

Rubius Therapeutics to Announce Second Quarter 2021 Financial Results

CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer a…

Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy

Preclinical Data Show RTX-240 Promotes T Cell and NK Cell Activity Demonstrating Efficacy and Improved Safety Compared with a 4-1BB Agonist Antibody Preclinical Data Show RTX-240 Promotes T Cell and NK Cell Activity Demonstrating Efficacy and Improved Safety Compared with a 4-1BB Agonist Antibody

Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors

CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that the firs…

Rubius Therapeutics to Participate in Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J.…

Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting

CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that the Compa…
Show more

Rubius Therapeutics Blogs

A Phase 1 Study of RTX-321, an Engineered Red Blood Cell as an Artificial Antigen-Presenting Cell Expressing HLA-A*02 with the HPV-16 E7 Peptide and 4-1BB Ligand with Membrane-Bound IL-12 for the Treatment of HPV 16-Positive Cancers

The post A Phase 1 Study of RTX-321, an Engineered Red Blood Cell as an Artificial Antigen-Presenting Cell Expressing HLA-A*02 with the HPV-16 E7 Peptide and 4-1BB Ligand with Membrane-Bound IL-12 for the Treatment of HPV 16-Positive Cancers appeared first on Rubius Therapeutics.

A Phase 1 Trial of RTX-240, an Allogeneic Engineered Red Blood Cell With Cell-Surface Expression of 4-1BBL and Trans-Presented IL-15, in Patients With Advanced Solid Tumors

The post A Phase 1 Trial of RTX-240, an Allogeneic Engineered Red Blood Cell With Cell-Surface Expression of 4-1BBL and Trans-Presented IL-15, in Patients With Advanced Solid Tumors appeared first on Rubius Therapeutics.

Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference

Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference Content Import Mon, 01/04/2021 - 16:01 Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference January 4, 2021 This release is a bac…

Rubius Therapeutics to Participate in Evercore ISI 3rd Annual HealthCONx Conference

CAMBRIDGE, Mass. , Nov. 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J.

Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts by the Boston Globe and Top 5 Best Places to Work in Rhode Island by Providence Business News

Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts by the Boston Globe and Top 5 Best Places to Work in Rhode Island by Providence Business News Brian.Hoenig@n… Fri, 11/20/2020 - 09:27 Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts by…

Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference

Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference Content Import Tue, 11/10/2020 - 16:02 Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference November 10, 2020 This release is a backfill from a…
Show more

Rubius Therapeutics Frequently Asked Questions

  • When was Rubius Therapeutics founded?

    Rubius Therapeutics was founded in 2013.

  • Who are Rubius Therapeutics key executives?

    Rubius Therapeutics's key executives are Pablo J. Cagnoni, Christina Coughlin and Andrew Oh.

  • How many employees does Rubius Therapeutics have?

    Rubius Therapeutics has 174 employees.

  • Who are Rubius Therapeutics competitors?

    Competitors of Rubius Therapeutics include ImCheck Therapeutics, Confo Therapeutics and Sigilon.

  • Where is Rubius Therapeutics headquarters?

    Rubius Therapeutics headquarters is located at 399 Binney St #300, Cambridge.

  • Where are Rubius Therapeutics offices?

    Rubius Therapeutics has offices in Cambridge and Smithfield.

  • How many offices does Rubius Therapeutics have?

    Rubius Therapeutics has 2 offices.